Compare VLTO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLTO | BIIB |
|---|---|---|
| Founded | 2023 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | VLTO | BIIB |
|---|---|---|
| Price | $100.75 | $170.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | $113.25 | ★ $177.40 |
| AVG Volume (30 Days) | 1.8M | ★ 2.0M |
| Earning Date | 02-03-2026 | 10-30-2025 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | ★ 12.64 | N/A |
| EPS | 3.65 | ★ 10.97 |
| Revenue | $5,452,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $8.28 | $3.61 |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $27.41 | ★ $15.68 |
| Revenue Growth | ★ 6.15 | 4.77 |
| 52 Week Low | $83.87 | $110.04 |
| 52 Week High | $110.11 | $185.17 |
| Indicator | VLTO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 48.08 |
| Support Level | $98.42 | $169.52 |
| Resistance Level | $101.08 | $175.94 |
| Average True Range (ATR) | 1.76 | 5.18 |
| MACD | 0.07 | -1.98 |
| Stochastic Oscillator | 54.67 | 12.20 |
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).